anthropic debuts preview
| |

Anthropic debuts preview of powerful new AI model Mythos in new cybersecurity initiative

Anthropic on Tuesday released a preview of its new frontier model, Mythos, which it says will be used by a small coterie of partner organizations for cybersecurity work. In a previously leaked memo, the AI startup called the model one of its “most powerful” yet.

The model’s limited debut is part of a new security initiative, dubbed Project Glasswing, in which 12 partner organizations will deploy the model for the purposes of “defensive security work” and to secure critical software, Anthropic said. While it was not specifically trained for cybersecurity work, the model will be used to scan both first-party and open source software systems for code vulnerabilities, the company said.

Anthropic claims that, over the past few weeks, Mythos identified “thousands of zero-day vulnerabilities, many of them critical.” Many of the vulnerabilities are one to two decades old, the company added.

Mythos is a general-purpose model for Anthropic’s Claude AI systems that the company claims has strong agentic coding and reasoning skills. Anthropic’s frontier models are considered its most sophisticated and high-performance models, designed for more complex tasks, including agent-building and coding.

The partner organizations previewing Mythos as part of Project Glasswing include Amazon, Apple, Broadcom, Cisco, CrowdStrike, the Linux Foundation, Microsoft, and Palo Alto Networks. As part of the initiative, these partners will ultimately share what they’ve learned from using the model so that the rest of the tech industry can benefit from it. The preview is not going to be made generally available, Anthropic said, though 40 organizations will gain access to the Mythos preview aside from the partnership.

Anthropic also claims that it has engaged in “ongoing discussions” with federal officials about the use of Mythos, although one would have to imagine that those discussions are complicated by the fact that Anthropic and the Trump administration are currently locked in a legal battle after the Pentagon labeled the AI lab a supply-chain risk over Anthropic’s refusal to allow autonomous targeting or surveillance of U.S. citizens.

News of Mythos was originally leaked in a data security incident reported last month by Fortune. A draft blog about the model (then called “Capybara”) was left in an unsecured cache of documents available on a publicly inspectable data lake. The leak, which Anthropic subsequently attributed to “human error,” was originally spotted by security researchers. “‘Capybara’ is a new name for a new tier of model: larger and more intelligent than our Opus models — which were, until now, our most powerful,” the leaked document said, adding later that it was “by far the most powerful AI model we’ve ever developed,” according to the report. 


In the leak, Anthropic claimed that its new model far exceeded performance areas (like “software coding, academic reasoning, and cybersecurity”) met by its currently public models and that it could potentially pose a cybersecurity threat if weaponized by bad actors to find bugs and exploit them (rather than fix them, which is how Mythos will be deployed).

Last month, the company accidentally exposed nearly 2,000 source code files and over half a million lines of code via a mistake it made in the launch of version 2.1.88 of its Claude Code software package. The company then accidentally caused thousands of code repositories on GitHub to be taken down as it attempted to clean up the mess.

Correction April 7, 2026: An earlier version of this article erroneously stated how many partners are working with Anthropic on Project Glasswing. There are 12 partner organizations, though 40 organizations total will have access to the Mythos preview.

Similar Posts

  • | |

    Nestle turns to AI to build products for weight lo…

    Nestle is working to convert the rapid rise of GLP-1 weight loss drugs from a business threat into an opportunity, deploying artificial intelligence and nutritional research to develop products aimed at the millions of consumers now taking medications like Ozempic and Wegovy. The fast growing adoption of drugs made by Novo Nordisk and Eli Lilly has raised concerns among investors that appetite suppressing medications could permanently dent demand for packaged foods, snacks and beverages. Nestle sees the same trend differently, believing the drugs are creating a new market for products that address the side effects associated with rapid weight loss. Chief Technology Officer Stefan Palzer told a foreign news agency that Nestle is using artificial intelligence and other technology to analyze clinical research, identify effective nutrient combinations and build products tailored specifically to GLP-1 users. He said the company believes its existing product portfolio positions it well to capture what he described as a major opportunity. Materials shown to reporters outlined side effects tied to rapid weight loss, including muscle loss and the loss of facial volume sometimes referred to informally as Ozempic face, along with areas where Nestle believes its products could help address those issues. The GLP-1 drug market remains dominated by Eli Lilly’s Mounjaro and Zepbound alongside Novo Nordisk’s Wegovy and Ozempic. Roughly 16 million Americans currently take GLP-1 medications, according to Boston Consulting Group, a number expected to grow significantly by the end of the decade. Nestle’s strategy centers on developing products suited to the needs of weight loss drug users while relying on AI to speed up research, product development and consumer analysis. Addressing side effects directly Palzer said Nestle scientists have spent time studying the downstream effects of rapid weight loss and building products intended to help consumers manage them. The company uses AI tools to process large volumes of clinical research and identify nutrient combinations that may support muscle health, hydration and overall nutritional intake. Nestle has already begun adding collagen protein to products under its Vital Proteins brand to address concerns about skin, hair and nail health linked to rapid weight loss. In the United States, Nestle’s business created the Boost Advanced Nutrition Shake, marketed as containing 35 grams of protein to support muscle health during weight loss. In Asia and Australia, the company introduced a higher protein version of its Milo malt drink called Milo PRO High Protein. Rival ice cream makers are grappling with similar pressures, shifting toward higher protein products, smaller portions and simpler ingredient lists. An AI powered recipe database Artificial intelligence plays an increasingly central role throughout Nestle’s product development process. The company has built internal systems to analyze scientific literature, simulate consumer behavior, spot emerging trends and help product developers navigate a database containing roughly 120,000 recipes. One such tool, an internal platform called Food Genie, helps scientists and developers predict how recipes might perform and identify opportunities for reformulation, according to Palzer. He said the scale of Nestle’s recipe database gives the company an advantage, noting that a smaller company with only a thousand recipes would struggle to model and predict outcomes using AI, since the technology depends heavily on large volumes of data. Nestle is also testing AI driven consumer simulations designed to predict how shoppers will respond to new products and health claims before they reach store shelves, and the company uses AI to monitor social media activity and identify emerging consumer trends. Palzer said the technology helps distinguish genuine, lasting trends from short term noise around particular topics, and said he expects AI to play a growing role in that kind of trend analysis going forward. Skepticism remains among some experts Not everyone is convinced specialized products offer meaningful advantages over conventional food. Amanda Avery, an associate professor of nutrition and dietetics at the University of Nottingham in central England, said it is unfortunate that consumers keep turning to new, more expensive products that often contain the same protein and nutrients found in whole, fresh foods. She noted that meat, fish, eggs, dairy, beans, nuts and pulses remain relatively affordable sources of protein and other nutrients. Even so, Avery said she expects products marketed specifically to GLP-1 users to find a ready customer base, acknowledging that marketing exerts significant influence over consumer choices and suggesting Nestle has likely done its homework before entering the space.

Leave a Reply

Your email address will not be published. Required fields are marked *